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Abstract Spinocerebellar ataxia type 31 (SCA31) is a
recently defined subtype of autosomal dominant cerebellar
ataxia (ADCA) characterized by adult-onset, pure cerebellar
ataxia. The C/T substitution in the 5′-untranslated region of
the puratrophin-1 gene (PLEKHG4) or a disease-specific
haplotype within the 900-kb SCA31 critical region just
upstream of PLEKHG4 has been used for the diagnosis of
SCA31. Very recently, a disease-specific insertion contain-
ing penta-nucleotide (TGGAA)n repeats has been found in
this critical region in SCA31 patients. SCA31 was highly
prevalent in Nagano, Japan, where SCA31 accounts for
approximately 42% of ADCA families. We screened the
insertion in 94 SCA31 patients from 71 families in Nagano.
All patients had a 2.6- to 3.7-kb insertion. The size of the
insertion was inversely correlated with the age at onset but
not associated with the progression rate after onset.
(TAGAA)n repeats at the 5′-end of the insertion were
variable in number, ranging from 0 (without TAGAA
sequence) to 4. The number of (TAGAA)n repeats was
inversely correlated to the total size of the insertion. The
number of (TAGAA)n repeats was comparatively uniform
within patients from the three endemic foci in Nagano.
Only one patient, heterozygous for the C/T substitution in
PLEKHG4, had the insertions in both alleles; they were
approximately 3.0 and 4.3 kb in size. Sequencing and
Southern hybridization using biotin-labeled (TGGAA)5
probe strongly indicated that the 3.0-kb insertion, but not
the 4.3-kb insertion, contained (TGGAA)n stretch. We also
found that 3 of 405 control individuals (0.7%) had the
insertions from 1.0 to 3.5 kb in length. They were negative
for the C/T substitution in PLEKHG4, and neither of the
insertions contained (TGGAA)n stretch at their 5′-end by
sequencing. The insertions in normal controls were clearly
detected by Southern hybridization using (TAAAA)5 probe,
while they were not labeled with (TGGAA)5 or (TAGAA)5
probe. These data indicate that control alleles very rarely
have a nonpathogenic large insertion in the SCA31 critical
region and that not only the presence of the insertion but
also its size is not sufficient evidence for a disease-causing
allele. We approve of the view that (TGGAA)n repeats in
the insertion are indeed related to the pathogenesis of
SCA31, but it remains undetermined whether a large
insertion lacking (TGGAA)n is nonpathogenic.
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Introduction
Spinocerebellar ataxia type 31 (SCA31), formerly known as
16q22.1-linked autosomal dominant cerebellar ataxia (16q-
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DOI 10.1007/s10048-010-0245-6ADCA), is a recently established subtype of ADCA charac-
terized by adult-onset, pure cerebellar ataxia [1–6]. SCA31
accounts for 8–17% of ADCA families and is the third most
predominant ADCA subtype after SCA6 and MJD/SCA3 in
Japan [7–11]. A single nucleotide substitution (–16C>T) in
the 5′-untranslated region (UTR) of the gene encoding
puratrophin-1 (PLEKHG4)h a sb e e ns h o w nt ob ea
disease-specific marker for 16q-ADCA [4, 5]. However, this
specific substitution has been found exclusively in the
Japanese population [12]; thus, it is still unclear whether
SCA31 exists in countries other than Japan.
TwopatientswithSCA31havebeenfoundnottocarrythis
substitution in PLEKHG4 [5, 13], indicating that it is not a
disease-causing mutation for SCA31. Thereafter, Amino et
al. [5] narrowed the SCA31 critical region to 900 kb
between rs11640843 (SNP04) and PLEKHG4 by fine single
nucleotide polymorphism (SNP) typing. Sato et al. [6]
identified an inserted sequence in this region, which was
confirmed in all SCA31 patients, without exception. The
insertion consists of complex penta-nucleotide repeats con-
taining (TGGAA)n, and the size of the insertion is variable,
ranging from 2.5 to 3.8 kb in length, among patients [6].
We have shown that SCA31 is the most predominant
subtype of ADCA in Nagano, which is located in the
central, mountainous district of the main island of Japan
[13–15], see Fig. 2]. To date, we have analyzed 168 ADCA
families from Nagano and diagnosed 71 families (42%)
with SCA31. Thus, the frequency of SCA31 in Nagano is
much higher than in other areas of Japan [7–11]. We have
found that SCA31 families are highly prevalent in
particular areas of Nagano, named as Kiso, Ina, and Saku
[13–15], see Fig. 2]. The ratio of SCA31 families to total
ADCA families in these areas was 14/16 (88%, Kiso area),
12/18 (67%, Ina area), and 17/25 (68%, Saku area).
Here, we have screened an insertion mutation for SCA31
in 94 patients from 71 families in Nagano.
Materials and methods
Subjects and clinical evaluation
We recruited 94 patients from 71 families with SCA31, and
these families most probably originated from Nagano. The
diagnosis of SCA31 was based on the presence of the C/T
substitution in PLEKHG4 (92 patients from 70 families).
Two patients (from two families) without the C/T substitu-
tion in PLEKHG4 were also included in this study because
they had a disease-specific haplotype in the 900-kb SCA31
critical region [13]. Forty-four of 71 families (62%)
originated from the three endemic foci described above.
Detailed medical interviews and routine neurological exami-
nations were performed by expert neurologists. Age at onset
was determined on the basis of the information provided by
the patients or their close relatives. Scales for the assessment
and rating of ataxia (SARA) were used for the assessment of
cerebellar ataxia. To minimize the interrater variability,
SARA was performed by either of two expert neurologists
(KY and YS) for 57 patients (67 times).
This research protocol was approved independently by
the Ethical Committee of Shinshu University School of
Medicine and by the Committee for Ethical Issues at
Yokohama City University Graduate School of Medicine.
Molecular analysis
The insertion sequence was amplified by PCR according to
the methods described by Sato et al. [6]. PCR products
were purified using a PCR purification kit (QIAGEN),
digested with HaeIII, and then separated on a 0.8% agarose
gel (25 V, 15 h). The size of the HaeIII fragment containing
the insertion was calculated with a DNA size marker
simultaneously electrophoresed as a reference. HaeIII-
undigested PCR products were separated in a 0.8% low-
melting agarose gel, and fragments of approximately 3.0 kb
were cut out and extracted using a QIA quick® Gel
Extraction Kit (QIAGEN). They were then directly se-
quenced by a standard protocol using BigDye terminator
(Applied Biosystems, Foster City, CA) on an ABI PRISM
3100 Genetic analyzer or an ABI PRISM 3500xL Genetic
analyzer (Applied Biosystems). HaeIII-undigested PCR
products were also separated in a 1% agarose gel, blotted
to a nylon membrane (Hybond
TM-N
+, Amersham Interna-
tional plc, Buckinghamshire, UK) using 10× SSC, and
subjected to Southern hybridization using biotin-labeled
(TGGAA)5, (TAGAA)5, or (TAAAA)5 as a probe. Detec-
tion was done with BrightStar
TM BioDetect
TM Nonisotopic
Detection Kit (Ambion Inc., Austin, TX) according to the
manufacturer’s instructions.
Statistics
The relationship between the size of the insert and the age
at onset was analyzed using Spearman’s correlation
coefficient by rank test. Regression analysis for SARA
data was also performed. Analysis of the differences in the
insert size among the groups was carried out using analysis
of variance and the post hoc test of Scheffé. The level of
significance was set at p<0.01.
Results
All of the patients recruited in this study had an insertion
ranging from 2.6 to 3.7 kb in length. Direct sequencing
confirmed that the insertion contained (TGGAA)n stretch in
410 Neurogenetics (2010) 11:409–415all of the patients. The average length of the insertions was
approximately 3,130 bp (SD, 199 bp) (n=94). The
correlation between the size of the insertion and the age at
onset is shown in Fig. 1. The length of the insertion was
inversely correlated with the age at onset (n=89). We
observed six intergenerational transmission of a disease-
causing allele in five families in our cohort. There was no
conspicuous expansion of the insertion size.
The average size of the insertion was obviously different
between patients from the three endemic foci (Fig. 2a, b).
The insertion of patients from Kiso area was significantly
shorter in length (2,866±132 bp, n=18) than those from the
other two areas (3,263±101 bp, n=27, Ina area; 3,111±
109 bp, n=18, Saku area).
We found the number of penta-nucleotide (TAGAA)n
repeats at the 5′-end of the insertion was variable, as well as
the subsequent (TGGAA)n repeats. The number of
(TAGAA)n repeats ranged from 0 to 4 (Fig. 3); the most
predominant number was 1 (50/94, 53%), followed by 2
(20/94, 21%), 3 (14/94, 15%), and 4 (8/94, 9%). There
were two patients without (TAGAA) sequence just up-
stream of (TGGAA)n repeats. The number of (TAGAA)n
repeats, if present, was inversely correlated with the size of
the insertion (Fig. 4). The repeat size of (TAGAA)n was
comparatively uniform within the endemic foci. Seventeen
of 18 patients (94%) in Kiso area had three or four
(TAGAA)n repeats. Twenty-five of 27 (93%) in Ina area
had one repeat, and all 18 patients (100%) in Saku area had
one or two repeats. Two patients without (TAGAA)
sequence originated from areas outside the three endemic
foci. We had 12 families, in which more than two affected
members were recruited in this cohort. Intrafamilial
variation in (TAGAA)n repeat number was observed only
in one family (family ID 166); the sister had four
Fig. 1 Correlation between the
insertion size and age at onset
(n=89). Representative PCR
screening for the SCA31 inser-
tion (a). Agarose gel electro-
phoresis of PCR products before
and after HaeIII digestion is
shown. M GeneRuler
TM 1-kb
Ladder (Fermentas Life Scien-
ces, Burlington, Canada). The
size of the insertion is inversely
correlated with the age at onset
(b). For 5 of 94 patients, age at
onset could not be clearly de-
fined by medical interview
Fig. 2 Distribution of the inser-
tion size in endemic foci in
Nagano. The location of the
three endemic foci (Kiso, Ina,
and Saku) in Nagano prefecture
is indicated (a). The distribution
of the size of insertions in the
three endemic foci is shown (b).
The distribution (vertical bar),
the average size (horizontal
bar), and the standard deviation
of the size of insertion (shaded
square) in all the patients (n=
94) are shown in left.
##p<0.01
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the number of (TAGAA)n repeats was consistent among the
family members in the other 11 families.
In our cohort, 93 patients were heterozygous for the
insertion, but only one patient aged 87 (patient ID 254)
carried the insertions in both alleles (Fig. 5). This patient
originated from one of three endemic foci, Kiso area, and
developed cerebellar ataxia at age 76. He was still able to
walk with a cane, and his SARA score was 15.5 at age 87.
The size of the insertions was calculated as approximately
3,040 and 4,280 bp. Direct sequencing showed that only
the 3.0-kb insertion, but not the 4.3-kb insertion, contained
(TGGAA)n stretch. By Southern hybridization, the 3.0-kb
insertion, but not the 4.3-kb insertion, was detected by
(TGGAA)5 probe (Fig. 6c). The 4.3-kb insertion was faintly
labeled with (TAGAA)5 probe, and the signal intensity was
much weaker than the 3.0-kb insertion (Fig. 6d). On the
Fig. 3 Sequence of the 5′-end of the insertion. The number of (TAGAA)n repeats (underlined in red) is variable, ranging from 0 to 4
Fig. 4 Correlation between the sizes of (TAGAA)n repeats preceding
(TGGAA)n repeats and the insertion size. ##p<0.01; #p < 0.05. n.s.
not significant
Fig. 5 PCR amplification for the insertion. The patient (ID 256, lane
5) had insertions on both alleles, instead of lacking a wild-type 1.5-kb
band without the insertion. The 4.3-kb band is indicated by the arrow
412 Neurogenetics (2010) 11:409–415other hand, the 4.3-kb insertion was more intensively
labeled with (TAAAA)5 probe than the 3.0-kb insertion
(Fig. 6b).
Furthermore, we found that 3 of 405 healthy control
individuals (0.7%) had the insertions (Fig. 6a, Table 1).
Neither of the insertions contained (TGGAA)n stretch at
their 5′-end by sequencing. By Southern hybridization, the
insertions in control individuals were not detected by
(TGGAA)5, or (TAGAA)5 probe (Fig. 6c, d), but were
more clearly labeled with (TAAAA)5 probe than the
insertions in SCA31 patients (Fig. 6b).
To see the effect of the insertion size on disease
progression, we tentatively divided the patients into three
groups based on the size of the insertion; groups I (insertion
size>3,300 bp, n=11), II (3,000–3,300 bp, n=27), and III
(<3,000 bp, n = 17). The correlation between SARA scores
and age at examination or duration of illness is shown in
Fig. 7. There was no significant difference in the disease
progression rate after onset between the groups.
Discussion
In the present study, we confirmed that all of the SCA31
patients in our cohort had the insertions of the penta-
nucleotide repeats found by Sato et al. [6]. The insertions
ranged from 2.6 to 3.7 kb in length, and contained
(TGGAA)n stretch at their 5′-end, without exception. We
also verified that the size of the insertion was inversely
correlated to the age at disease onset in our large cohort.
Fig. 6 Southern hybridization for the insertion. HaeIII-undigested
PCR products were separated in a 1% agarose gel, stained with
ethidium bromide (a), and then blotted to a nylon membrane. The
membrane was hybridized with biotin-labeled (TAAAA)5 probe (b),
(TGGAA)5 probe (c), or (TAGAA)5 probe (d). The insertions in
SCA31 patients (lanes 1–3) were clearly detected by (TGGAA)5 or
(TAGAA)5 probe (c and d) . In patient ID 254 (lane 3), the 3.0-kb
insertion (arrow), but not the 4.3-kb insertion (arrowhead), was
clearly labeled with (TGGAA)5 probe (c). In contrast, the 4.3-kb
insertion (arrowhead), as well as the insertions in normal controls
(lanes 4–6), was more intensively labeled with (TAAAA)5 probe than
the insertions in SCA31 patients (b). The 1.5-kb fragments derived
from a normal allele were visualized by (TAAAA)5 probe (b) because
(TAAAA)n repeats are included in the original genomic sequence.
Lanes 1–3 ,SCA31 patients (lane 3, patient ID 254); lanes 4–6,
control individuals with the insertion (lane 4: control 1; lane 5: control
2; lane 6: control 3 in Table 1); lanes 7 and 8, control individuals
without the insertion
Table 1 The haplotypes of SCA31 patients and control subjects
Polymorphic marker
(site on NCBI Build 36.3)
AB473220
(65,049,291)
Complex penta-nucleotide repeat insertion
[insertion size] (65,081,803)
AB473217
(65,114,245)
–16C/T puratrophin-1
(65,871,433)
Reference sequence G – GC
Frequencies in controls
a G 99.2% G 100% C 100%
A 0.8% C 0.0% T 0.0%
Homozygous patient
a A5 ′ TCAC (TGGAA)n (TAAAA TAGAA)n– CT
Patient (ID 254)
b A5 ′ TCAC TAAAA (TAGAA)4 (TGGAA)n – [3,040 bp] G/C C/T
5′ TCAC TAACA (TAAAA)n – [4,280 bp]
Control 1
b G/A 5′ TCAC TAACA (TAAAA)n – [3,520 bp] G C
Control 2
b G5 ′ (TAAAA)n – [2,540 bp] G C
Control 3
b G5 ′ (TAAAA)n – [1,070 bp] G C
aSato et al (2009)
bThis study
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associated with the disease progression rate after onset.
We found that the penta-nucleotide (TAGAA)n repeats at
the 5′-end of the insertion were variable in number, as were
the subsequent (TGGAA)n repeats. Interestingly, the num-
b e ro f( T A G A A ) n repeats, if present, was inversely
correlated with the total size of the insertion. Furthermore,
the repeat size of (TAGAA)n is comparatively uniform
within the endemic foci. From the geographical viewpoint,
we previously supposed that there were two major foci in
the southwest (Ina–Kiso) and east (Saku) areas in Nagano
[15], but patients in Ina and Kiso areas are likely to be
different from the viewpoint of population genetics because
the number of (TAGAA)n repeats and the size of the
insertion were obviously different between the two groups.
In our cohort, only one patient (patient ID 254) was
homozygous for the insertion in the SCA31 critical region
as determined by PCR analysis (Fig. 5, Table 1). Contrary
to our expectation, sequencing showed that only the smaller
3.0-kb insertion had (TGGAA)n stretch. This was also
confirmed by Southern hybridization using biotin-labeled
(TGGAA)5 probe. The patient developed gait ataxia at
approximately age 76 and showed pure cerebellar ataxia by
neurological examination at age 87. His clinical features
were typical for SCA31 [7–11, 13, 15]. As his parents died
a long time ago, we could not obtain reliable information
on his parents or their genomic DNA. It is confusing that he
was heterozygous for the C/T substitution in PLEKHG4 but
was homozygous for a disease-specific G/A substitution at
AB473220 (Table 1).
Moreover, three control individuals had the insertions
ranging from 1.0 to 3.5 kb in length. Sequencing and
Southern hybridization indicated that these insertions did
not contain (TGGAA)n or (TAGAA)n repeats. Information
on the family history of cerebellar ataxia was not available
for these control individuals because they voluntarily
participated in this study as anonymous healthy controls.
Neither of them carried the C/T substitution in PLEKHG4,
but one control individual (control 1 in Table 1) had G/A
substitution at AB473220 and a large insertion (3,520 bp)
indistinguishable from SCA31 patients. Sato et al. [6] have
shown that the insertion in the SCA31 critical region is
rarely observed in control individuals but that the insertion
in control individuals is shorter in length than SCA31
patients and lacks (TGGAA)n stretch. At present, however,
we do not completely exclude the possibility that the 4.3-kb
insertion in patient ID 254 and the 3.5-kb insertion in
control 1 have some pathogenic effects, although these
insertions are likely to lack (TGGAA)n stretch.
In summary, our data clearly indicate that not only the
presence of the insertion but also the size of the insertion in
the SCA31 critical region is insufficient evidence for the
disease-causing allele. They may support the hypothesis by
Sato et al. that the presence of (TGGAA)n repeats is
important for the pathogenesis of SCA31. However, it is
possible that a large insertion without (TGGAA)n repeats
may have a pathological significance, requiring further
investigation. The control individual with such insertion in
this study may potentially develop cerebellar ataxia in the
future, considering that SCA31 is a late-onset disease. The
insertion sequences in SCA31 patients consist of
(TAGAA), (TGGAA), and (TAAAA) penta-nucleotide
repeats of variable numbers [6], but the precise pathogen-
esis by the penta-nucleotide repeat insertion remains
unclear in SCA31. Further detailed characterization of the
inserted sequence and data on genotype–phenotype corre-
lation will be needed.
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Fig. 7 Correlation between SARA and age at examination (a)o r
duration of disease (b) in SCA31 patients. The patients were divided
into three groups based on the size of insertion; groups I (insertion
size >3,300 bp, closed square), II (3,000–3,300 bp, open circle), and
III (<3,000 bp, open triangle). SARA was performed 14 times in 11
patients from group I, 34 times in 29 patients from group II, and 19
times in 17 patients from group III. Broken, solid, and dotted lines
indicate linear regression lines for groups I, II, and III, respectively
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